OncoSNIPE - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients

CANCER Clinical Trial

— OncoSNIPE  

Official title:

Molecular Profiles Associated With Resistance Development in Cancer Patients. Prospective Exploratory Study From 3 Cancer Locations: TNBC or Locally Advanced or Metastatic, Non-small Cell or Pancreatic or Bronchial Cancers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04548960
• Other study ID #: 2017-A02018-45
• Status: Recruiting
• Phase: N/A
• Start date: January 6, 2018
• Est. completion date: March 31, 2023

Study information

• Verified date: September 2020
• Source: Oncodesign SA
• Contact: PHILIPPE GENNE, PhD
• Phone: +33 3 80 78 82 60
• Email: PMONGIN[@]ONCODESIGN.COM
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Precision medicine is considered to be one of the major issues in patient care. A lot of research has already proven itself with the implementation of targeted therapies including immunotherapies offering patients improved response and survival rates. But despite these major therapeutic advances, resistance to anti-cancer treatment is a major obstacle in the care of patients. Indeed, to date, many patients die of cancer, 9.6 million deaths worldwide in 2018. Nowadays, improving understanding of the mechanisms of resistance of cancer cells to anti-tumor treatments is therefore a major issue. The great diversity of molecular mechanisms involved in the phenomena of resistance to treatment, whether intrinsic (de novo, or primary) or acquired (secondary), constitutes a real therapeutic challenge. Indeed, a better understanding of the mechanisms of resistance would make it possible to explore new therapeutic strategies making it possible to circumvent these phenomena of escape in different types of cancer. It is in this context that the OncoSNIPE project was developed. The objective of this project is to identify early and / or late markers of resistance to treatment in 3 different pathologies concerned with resistance issues: triple negative breast cancer or Lum B or locally advanced or metastatic non -small-cell lung cancer or pancreatic cancer. In this project, in order to best cover the diversity of mechanisms involved in these resistances, the investigators propose a multidisciplinary approach with clinical, genomic, transcriptomic and immunological dimensions of the pathology through the data collected from 600 patients (200 for each pathology) for 4 years

Description:

Precision medicine is considered to be one of the major issues in patient care. A lot of research has already proven itself with the implementation of targeted therapies including immunotherapies offering patients improved response and survival rates. But despite these major therapeutic advances, resistance to anti-cancer treatment is a major obstacle in the care of patients. Indeed, to date, many patients die of cancer, 9.6 million deaths worldwide in 2018. Nowadays, improving understanding of the mechanisms of resistance of cancer cells to anti-tumor treatments is therefore a major issue. The great diversity of molecular mechanisms involved in the phenomena of resistance to treatment, whether intrinsic (de novo, or primary) or acquired (secondary), constitutes a real therapeutic challenge. Indeed, a better understanding of the mechanisms of resistance would make it possible to explore new therapeutic strategies making it possible to circumvent these phenomena of escape in different types of cancer. It is in this context that the OncoSNIPE project was developed. The objective of this project is to identify early and / or late markers of resistance to treatment in 3 different pathologies concerned with resistance issues : triple negative breast cancer or lum B or locally advanced or metastatic non- small-cell lung cancer or pancreatic cancer. In this project, in order to best cover the diversity of mechanisms involved in these resistances, the investigators propose a multidisciplinary approach with clinical, genomic, transcriptomic and immunological dimensions of the pathology through the data collected from 600 patients (200 for each pathology) for 4 years. The patient populations targeted in this study have one common thing: rapid progression of their pathology, making it possible to obtain models for evaluating markers of early and / or late responses over the period of follow-up of 2-year post-inclusion patients, and thus provide the information necessary to understand the resistance mechanisms. To explore the phenomena of resistance, during the therapeutic response and / or the progression of the pathology, the investigators will used a multidisciplinary approach including high-throughput sequencing (Exome-seq and RNAseq) and immunological profil by ELISA . Patients will have long-term follow-up with different biological samples, at baseline (blood and biopsy) and at each tumoral evaluation or tumoral progression evaluated by medical imaging.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: March 31, 2023
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. General

• Adult patient, 18 years of age or older
• Naive chemo patient
• Performant status: 0,1 or 2.
• Life expectancy> 3 months
• Subject affiliated to a social security and health insurance scheme
• Subject having dated and signed informed consent
• For women of childbearing age (negative pregnancy test): effective contraception

2. Pancreatic cancer:

• Patient receiving a biopsy, as part of the usual care of the patient:
• Either from the primary tumor
• Either a metastasis for a strong suspicion of locally advanced or metastatic pancreatic ductal adenocarcinoma;
• With advanced or metastatic tumors (liver, lungs, peritoneum, others) that cannot benefit from local or locoregional treatment;
• Presence of target lesion (s) measurable according to RECIST criteria
• Patient who cannot be treated by surgery or radiotherapy

3. Lung cancer:

• Patient with histologically proven non-small cell lung cancer
• Locally advanced stage IIIB or IV
• Treatment with chemotherapy, targeted therapy, immunotherapy
• Tissue available after analysis of the usual biomarkers in the event of a non-epidermoid tumor
• Rate of tumor cells observed on biopsies must be = 30%.
• Presence of measurable target lesion or disease assessable according to RECIST criteria

4. Breast cancer:

• Breast cancer of recent diagnosis, histologically proven.
• Triple negative breast cancer: negativity of estrogen and progesterone receptors in the tumor (<10%), absence of HER2 overexpression according to the IHC classification (score 0 or 1+) and / or FISH negative
• or
• LumB: RO positive, RP positive or negative, HER2 negative, high proliferation;
• Stage I to III for triple negative breast cancer (including stage T4d = inflammatory cancer), Stage II or III of the UICC classification for LumB
• Non-metastatic patient (M0 according to TNM classification)
• Rate of tumor cells observed on biopsies must be = 30%
• Patient who cannot be treated exclusively by surgery or radiotherapy Exclusion Criteria: General
• History of chemotherapy (except adjuvant completed for more than at least 6 months) or radiotherapy
• Patient whose monitoring and treatment will not be carried out in the study health establishments;
• Tumor not histologically proven;
• Life expectancy of less than 3 months
• Pregnancy or breastfeeding
• Refusal to participate in the trial
• Persons deprived of their liberty, persons under guardianship or curatorship
• Inability to submit to the medical follow-up of the test for social or psychological reasons
• No affiliation to a social security scheme or state medical aid (AME) or universal medical coverage (CMU)
• Any condition for which participation in the protocol would present a risk or which would not make it possible to comply with the requirements of the protocol according to the investigator
• History of other cancers in the last 5 years except cervical cancer and skin cancer of the basal or epidermoid cells treated
• Known HIV seropositivity Specific

Pancreatic cancer:

• Other histologies: neuroendocrine cancer, acinar cancer, pancreatic metastasis of another cancer
• Patient who cannot benefit from chemotherapy (Performans status (PS) 3 - 4);
• Other progressive cancer during the management of pancreatic cancer;

Related Conditions & MeSH terms

• CANCER

Intervention

Other:
• cancer patients
Blood sample RNA_seq at time of diagnostic, best response and relapse ; Biopsy Exom_seq and RNA_seq at time of diagnostic and relapse Immulogical Profiling at time of diagnostic, best response and relapse

Locations

Country	Name	City	State
France	Chu de Besancon	Besancon	Bourgogne Franche Comte
France	APHP - Hôpital Beaujon	Clichy	Paris
France	CGFL	Dijon	Bourgogne Franche Comte
France	Chu Dijon Bourgogne	Dijon	Bourgogne Franche Comte
France	Centre Leon Berard	Lyon	Auvergne-Rhône-Alpes
France	Institut Paoli Calmettes	Marseille	Paca
France	Institut de Cancerologie de Lorraine	Nancy	Grand EST
France	Institut Curie	Paris
France	Chu de Poitiers	Poitiers	Nouvelle-Aquitaine
France	Institut Godinot	Reims	Grand EST
France	Hopitaux Universitaires de Strasbourg	Strasbourg	Grand EST

Sponsors (1)

Lead Sponsor	Collaborator
Oncodesign SA

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Combinatory analysis of genomic, transcriptomic and immunological profile	Genomic changes associated with early and/or late resistance to treatment given alone or in combination in patients [ Time Frame: Through study completion, up to 2 years ]; Transcriptomic changes associated with early and/or late resistance to treatment given alone or in combination in patients [ Time Frame: Through study completion, up to 2 years ]; Immunophenotypic changes associated with early and/or late resistance to treatment given alone or in combination in patients [ Time Frame: Through study completion, up to 2 years ]	up to 24 months
Secondary	Progression-free survival	Clinical data from Baseline until 24 months	up to 24 months
Secondary	Over Survival	Clinical data from Baseline until 24 months	up to 24 months

External Links

•   OncoSNIPE Program description